Manages moderately severe acute pain. ANDA 216651, held by Hetero Labs Ltd Iii. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 216651 (Ketorolac Tromethamine), held by Hetero Labs Ltd Iii, was first approved by FDA on Aug 25, 2022, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Acute Pain in Adult Patients Ketorolac Tromethamine Tablets are indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ketorolac Tromethamine10MG · tablet;oral | Ketorolac Tromethamine | Rx |
| Nov 21, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 25, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters